UK’s growing synthetic opioid problem: Nitazene deaths could be underestimated by a third
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-May-2026 15:15 ET (30-May-2026 19:15 GMT/UTC)
Deaths due to synthetic opioids nitazenes have likely been underestimated by up to a third.
A new study conducted during the Israel-Hamas war reveals that a teacher's subjective sense of stress and helplessness is a far stronger predictor of burnout than their actual physical exposure to war-related events. By surveying 329 Jewish and Arab educators, the research identified "cognitive reappraisal," the ability to mentally reframe difficult situations, as a vital protective factor that lessens the impact of war exposure on professional exhaustion. These findings suggest that personal resilience can be strengthened through targeted workshops, helping teachers maintain their mental health and efficacy during chronic national crises.
https://doi.org/10.1016/j.apsb.2025.11.025
This new article publication from Acta Pharmaceutica Sinica B, discusses therapeutic drug monitoring of biologics in inflammatory bowel disease.
https://doi.org/10.1016/j.apsb.2025.10.028
This new article publication from Acta Pharmaceutica Sinica B, discusses how structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity.
https://doi.org/10.1016/j.apsb.2025.10.027
This new article publication from Acta Pharmaceutica Sinica B, discusses how palmitoylation of Tfr1 enhances platelet ferroptosis and liver injury in heat stroke.
https://doi.org/10.1016/j.apsb.2025.09.037
This new article publication from Acta Pharmaceutica Sinica B, discusses an Oxygen-boosted dual-section microneedle patch for enhanced drug penetration and improved photodynamic and anti-inflammatory therapy in psoriasis.
https://doi.org/10.1016/j.apsb.2025.11.026
This new article publication from Acta Pharmaceutica Sinica B, discusses how neg-entropy is the true drug target for chronic diseases.
https://doi.org/10.1016/j.apsb.2025.09.026
This new article publication from Acta Pharmaceutica Sinica B, discusses the discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model.